Nacionalinė farmacijos pramonės asociacija - financials and debts

Company age: 20 y. 6 mo.

Update

Company finances

EUR
2021
From: 2021-01-01
To: 2021-12-31
2022
From: 2022-01-01
To: 2022-12-31
2023
From: 2023-01-01
To: 2023-12-31
2024
From: 2024-01-01
To: 2024-12-31
2025
From: 2025-01-01
To: 2025-12-31
Financial data
Sales revenue - 1,100 1,100 1,100 1,200
Profit before tax - 59 58 -43 -42
Net profit - 59 58 -43 -42
Equity 33 92 149 106 64
Liabilities - 0 0 0 -
Non-current assets - - - - -
Current assets - - - - -
Total assets 0 0 0 0 0
Financial indicators
Revenue change y/y - - +0.0% +0.0% +9.1%
ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. - - - - -
ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. - 64.1% 38.9% -40.6% -65.6%
Profit margin Net profit margin. Shows the overall profitability of the company. - 5.4% 5.3% -3.9% -3.5%
EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. - 5.4% 5.3% -3.9% -3.5%
Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. - - - - -
Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. - - - - -

Purchase full financial statements

Profit/Loss, Balance Sheet, Cash Flow, Equity

9.99 € + PVM Buy

See Scoris data in Google Search

Mark Scoris as a favorite source. One click, no registration.

Social security debts

The company had no debts to Sodra

VMI tax arrears

The company had no tax arrears (debts) to the State Tax Inspectorate

VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.

Analysis of the company's financial position

This description was generated by artificial intelligence. Report if inaccurate.
Nacionaline farmacijos pramones asociacija (code 300553096) is an Association operating in market research and public opinion polling. In 2025, it generated €1.2K in revenue, up 9.1% year on year from €1.1K in 2024. The company reported a net loss of €42 in 2025, compared with a loss of €43 in 2024 and a profit of €58 in 2023. This shows a transition from a small profit to modest losses over the last two years, while revenue remained broadly stable. The 2025 profit margin was -3.5%, indicating that operating results were slightly below breakeven. Equity declined from €149 in 2023 to €106 in 2024 and €64 in 2025, reflecting the cumulative effect of the recent losses. The reported return on equity was negative in 2025, but this should be viewed in the context of the very small equity base. No asset, liability, or staff figures were provided.